WLWenjie Lu

Wenjie Lu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenjie Lu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Kezhong Tang

    Zhejiang Univ, Dept Hepatopancreatobiliary Surg, Affiliated Hosp 2, Sch Med, Hangzhou 310000, Zhejiang, Peoples R China

    3 shared publications
  • Lantian Wang

    Zhejiang Univ, Dept Hepatopancreatobiliary Surg, Affiliated Hosp 2, Sch Med, Hangzhou 310000, Zhejiang, Peoples R China

    3 shared publications
  • Hanyun Zhang

    Department of Gastroenterology, Second Affiliated Hospital of Zhejiang University, Hangzhou, China

    2 shared publications
  • Bin Xu

    Zhejiang Univ, Dept Hepatopancreatobiliary Surg, Affiliated Hosp 2, Sch Med, Hangzhou 310000, Zhejiang, Peoples R China

    1 shared publication
  • Bin Xu

    Department of Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    1 shared publication
  • Bin Yang

    Zhejiang Univ, Dept Hepatopancreatobiliary Surg, Affiliated Hosp 2, Sch Med, Hangzhou 310000, Zhejiang, Peoples R China

    1 shared publication

Latest Publications

  • Open Access

    Combining ferroptosis inducers with gemcitabine to enhance treatment efficacy in pancreatic cancer

    by Hanyun Zhang, Wenjie Lu

    Gemcitabine (GEM) is a standard chemotherapy for pancreatic cancer, but resistance limits its clinical benefit. The role of SRRM1, a splicing regulator, in


    • 15 June 2023
      • Vol. 15  (6) , 4314-4331

    LncRNA SNHG20 silencing inhibits hepatocellular carcinoma progression by sponging miR-5095 from MBD1

    by Bin Xu, Chao Li, Bin Yang, Fan Zhou, Kezhong Tang, Lantian Wang, Wenjie Lu

    Objective: Long non-coding RNAs (lncRNAs) may have a significant regulatory effect on the progression of hepatocellular carcinoma (HCC), according to recent data. This study aims to investigate how SNHG20, a small nucleolar RNA host gene, contributes to the development of HCC. Methods: LncRNA SNHG20, miR-5095, and MBD1 gene levels were determined using reverse transcription qPCR (RT-qPCR). Huh-7 and HepG2 cell bioactivities were evaluated using the CCK-8 kit, EdU, flow cytometry, and wound-healing migration tests. To assess the metastasis of Huh-7 and HepG2 cells, a transwell assay was used. The amounts of invasion- and proliferation-associated proteins were determined using western blot. Using the miRDB (www.mirdb.org) software, the possible target genes of lncRNA and miRNA were predicted, and this prediction was then verified by a twofold luciferase reporter test. To determine the pathologic alteration and Ki67 level in tumor tissues, H&E staining and IHC were employed. TUNEL was conducted to assess the presence of apoptotic bodies in the tumor tissues. Results: lncRNA SNHG20 exhibited a high expression in HCC cells (P<0.01). LncRNA SNHG20 knockdown inhibited HCC cell metastasis (P<0.01) and accelerated apoptosis (P<0.01). LncRNA SNHG20 acted as a sponge of miR-5095 in HCC. In addition, miR-5095 overexpression inhibited HCC cell metastasis (P<0.01) and accelerated apoptosis (P<0.01); and miR-5095 negatively targeted MBD1. Furthermore, LncRNA SNHG20 regulated HCC progression through the miR-5095/MBD1 axis, and LncRNA SNHG20 knockdown inhibited HCC growth. Conclusion: LncRNA SNHG20 accelerates HCC progression by the miR-5095/MBD1 axis, indicating lncRNA SNHG20 can be used as a biomarker for patients with HCC.


  • Open Access

    Elderly Pancreatic Adenocarcinoma Cancer Patients Could Benefit From Postoperative Chemotherapy

    by Bin Xu, Jinbo Shi, Wenjie Lu, Yulian Wu, Xin Dong

    Objectives: The study aim to investigate whether elderly patients with resectable pancreatic ductal adenocarcinoma (PDAC) could benefit from postoperative chemotherapy. Methods: This study selects the data of PDAC patients who were diagnosed between 2004 and 2014 from the Surveillance, Epidemiology, and End Results program. Median overall survival (mOS) is determined by Kaplan-Meier survival curves. Multivariate logistic regression analysis and hazard ratio are employed to assess the association among potential prognostic factors. Propensity score matching evaluation is used to reduce bias. Results: In total, there are 11,865 PDAC patients selected from the Surveillance, Epidemiology, and End Results database. Elderly PDAC patients have poor prognoses compared with younger (mOS, 15 vs 21 months). The possible reason might be that the elderly patients are less likely to receive postoperative chemotherapy. After propensity score matching, it is found that, for those who receive postoperative chemotherapy, although the mOS of older group is not as good as that of the younger group (mOS, 20 vs 23 months; 18-month survival rate: 53.4% vs 61.3%), the mOS of older group prolonged by postoperative chemotherapy is similar to that of younger group (9 vs 9 months). Conclusions: Elderly PDAC patients (≥70 years) might benefit from the currently used postoperative chemotherapy regimens.


  • Open Access

    Combination of Metformin and Sorafenib Induces Ferroptosis of Hepatocellular Carcinoma Through p62-Keap1-Nrf2 Pathway

    by Kezhong Tang, Qing Chen, Yanmo Liu, Lantian Wang, Wenjie Lu

    Hepatocellular carcinoma (HCC) is one of the most lethal cancers in the world. Sorafenib is the first small-molecule multi-kinase inhibitors approved by FDA for treatment of advanced HCC. Metformin has been demonstrated to have benefit for preventing cancer progression. In human recurrent HCCs, NF-E2-related factor 2 (Nrf2) was overexpressed and associated with poor survival. Nrf2 related signaling pathway plays central role to mediate cellular resistance to sorafenib through protecting HCC cells from ferroptosis. The effect of Combination treatment for HCC cells and the intrinsic mechanism have not been reported. In this study, metformin augmented the anti-tumor effect of sorafenib for HCC through ferroptosis induction by inhibiting Nrf2 related pathway. Based on the results of Nrf2 knockdown and p62 knockdown study, the combination of sorafenib and metformin suppressed proliferation of HCC cells through p62-Keap1-Nrf2/HO1 signaling way. Size of xenografts treated with the combination of sorafenib and metformin was smaller than other groups in vivo. Moreover, the combination treatment greatly induced ferroptosis in HCC cells through inhibiting Nrf2 expression. Based on our findings, the combination treatment suppressed proliferation of HCC cells through ferroptosis induction, by p62-Keap1-Nrf2/HO1 signaling way.


  • Anti-PD-1-based immunotherapy plus lenvatinib to treat advanced gallbladder cancer in the elderly: a case series and review of current literature

    by Lantian Wang, Kezhong Tang, Xiawei Li, Wenjie Lu

    Background Gallbladder cancer (GBC) is a rare malignant tumour of the bile duct. Due to the lack of typical clinical manifestations in the early stage, it is basically at an advanced stage when discovered. Radical resection remains the only curative therapy for patients with GBC. The resection rate is relatively low due to tumour invasion and metastasis, and the overall prognosis is poor. For most patients with unresectable lesions, chemotherapy has been the only recommended treatment for decades. Immunotherapy combined with TKIs (tyrosine kinase inhibitors) was proven to be effective in patients with hepatocellular carcinoma and cholangiocarcinoma. Some physicians have attempted to apply immunotherapy and TKIs combined with traditional chemotherapy in patients with advanced GBC. However, the outcomes were not clear because limited cases were reported. Case presentation We present a case series of four elderly patients with advanced GBC who received tislelizumab and lenvatinib combined with chemotherapy. All four patients responded to this treatment approach. Tumour responses were better in Patient 1 (TMB-H, MSS), Patient 2 (low TMB, MSS), and Patient 3 (low TMB, MSI-H) than in Patient 4 (low TMB, MSS), in whom metastasis occurred during the later stage of treatment. Conclusion The combination of tislelizumab and lenvatinib may be a promising treatment for patients with advanced GBC. The efficacy and safety need further confirmation.


  • LncRNA SNHG12 regulates gastric cancer progression by acting as a molecular sponge of miR‑320

    by Hanyun Zhang, Wenjie Lu

    Gastric cancer (GC) is one of the most common malignancies worldwide. Previous studies have focused on long non-coding RNAs (lncRNAs), which have important roles in the development and progression of GC. The present study aimed to clarify the expression and function of lncRNA small nucleolar RNA host gene 12 (SNHG12) in GC. The expression and the clinical characteristics of GC were analyzed in the samples from patients with GC and matched adjacent normal tissues. The present study determined that SNHG12 was significantly overexpressed in GC and its expression level was highly associated with tumor size, tumor-node-metastasis stage, distant metastasis, lymphatic metastasis. Patients with high SNHG12 expression had a short survival period. Additionally, inhibition of SNHG12 in GC cell lines SGC-7901 and AGS suppressed cell growth, colony formation, proliferation and invasion. MicroRNA (miR)-320, a putative target gene of SNHG12, was inversely correlated with SNHG12 expression in GC tissues and cell lines. In addition, the present study determined that miR-320 was directly regulated by SNHG12 and suppression of miR-320 expression reversed the inhibitory effects of SNHG12 siRNA on GC cell proliferation and invasion. These findings revealed that SNHG12 acts as a tumor promoter by directly targeting miR-320 in GC, suggesting a potential novel biomarker for the diagnosis and prognosis of GC.